Investigating Association Between Sociographic Factors and Rates of Urine Drug Screening in Patients Admitted to Labor and Delivery: A Retrospective Analysis

E. Manglardi, MD, MPH, D. Boucher, MD

Background


- The National Institute of Public Health reports about 5% of pregnant women admitting to substance use at some point throughout her pregnancy
- Rates of stillbirth are estimated to increase anywhere from 1.8 2.8x with drug use in pregnancy
- Professional organizations encourage healthcare providers to implement universal drug and alcohol screening in pregnancy
- In the state of Florida, drug use in pregnancy is considered child abuse, however the state does not require reporting or testing

Objective

Determine if there is an association between sociographic factors and rates of urine drug screening upon admission to labor and delivery.

Methods

- Retrospective cohort study
- All patients admitted to labor and delivery for delivery of their newborn between January 2016-December 2021 to five hospitals in the North Florida region
- Delivery information pulled from electronic medical records and deidentified
- CPT & ICD codes used
- Demographic data included age, race, body mass index (BMI) and insurance status
- Pregnancy complications: no prenatal care, hypertensive disorder, placental abruption, altered mental status, preterm labor, fetal demise and history of substance use



Results

UDS was performed on 22.7% of patients and 15.4% of patients admitted to substance use.

Demographic Data:

- Race/Ethnicity: 22.7% African American, 11.1% Hispanic, 58.1% White, 8.1% Other or Unspecified
- <u>Insurance:</u> 49.4% (*n*=6,344) government, 37.8% (*n*=4337) private, 12.8% other or uninsured

Table 1: Frequency of Urine Drug Screening by Substance Use and Insurance

				UDS					
				No		Yes			
				Count	Column N %	Count	Column N %	Test Statistic	p-value
Substance Use	No	Insurance	Government	3775a	43.8%	1324b	58.8%	243.957	<.001
			Other	948a	11.0%	296b	13.1%		
			Private	3753a	43.5%	576b	25.6%		
			Uninsured	144a	1.7%	56b	2.5%		
	Yes	Insurance	Government	768a	58.0%	477 b	73.6%	69.439	<.001
			Other	113a	8.5%	60a	9.3%		
			Private	430a	32.5%	98b	15.1%		
			Uninsured	13a	1.0%	13a	2.0%		

Of all patients that were drug screened and DID NOT admit to substance use, 58.8% were insured by the government while 25.6% had private insurance

Table 2: Frequency of Urine Drug Screening by Substance Use and Race

					No	Yes			
				Count	Column N %	Count	Column N %	Test Statistic	p-value
Substance Use	No	Race	Black	1977a	22.9%	653b	29.0%	380.881	<.001
			Hispanic	811a	9.4%	492b	21.8%		
			Other	427a	5.0%	134a	6.0%		
			Unspecified	280a	3.2%	68a	3.0%		
			White	5125a	59.5%	905b	40.2%		
	Yes	Race	Black	159a	12.0%	128b	19.8%	28.907	<.001
			Hispanic	76a	5.7%	48a	7.4%		
			Other	45a	3.4%	10b	1.5%		
			Unspecified	46a	3.5%	24a	3.7%		
			White	998a	75.4%	438b	67.6%		

Note: Values in the same row and subtable not sharing the same subscript are significantly different at p< .05 in the two-sided test of equality for column

Of all patients that were drug screened and DID NOT admit to substance use, 50.8% identified as African American or Hispanic.





Discussion

ACOG statement: routine urine drug screening in pregnancy is controversial and recommends testing only be performed with patient consent.

Equitable Surveillance vs Effective Treatment

- Equitable surveillance argues that screening for drug and alcohol use for all patients in early pregnancy will function as a surveillance method for reporting to CPS at time of delivery ²
- Effective treatment suggests universal screening allows for early identification and treatment of patients in pregnancy, resulting in the number of women reported at delivery ²

A study from 1990 showed similar rates of a positive drug screen between black and white women at both public and private clinics

- However, even with these findings, black women were reported to CPS at a rate ten times higher than white women ³
- Standardizing the utilization of UDS upon hospital admission is a necessary to eliminate unconscious bias when selecting which patients to screen

Universal screening for all patients may seem like an easy solution, but the additional costs associated, and effects of false positive need to be considered.

Conclusion

Urine drug screening in pregnancy is not universally recommended and there are no guidelines available to determine what patients require screening.

In the North Florida region, there are more patients screened that are Black, Hispanic or have government insurance. This area may benefit from a UDS protocol upon admission to labor and delivery.

References

1. Tobacco, drug use in pregnancy can double risk of stillbirth. *National Institute of Health*.

https://www.nih.gov/news-events/news-releases/tobacco-drug-use-pregnancy-can-double-risk-stillbirth.

2. Substance Use While Pregnant and Breastfeeding. *National Institute of Health*.

https://nida.nih.gov/publications/research-reports/substance-use-in-women/substance-use-while-pregnant-breastfeeding#:~:text=Estimates%20suggest%20that%20about%205,one%20or%20more%20addictive%20substances.&text=Regular%20use%20of%20some%20drugs,goes%20through%20withdrawal%20upon%20birth.

3. Roberts S, Nuru-Jeter A. Universal Alcohol/Drug Screening in Prenatal Care: A Strategy for Reducing Racial Disparities? Questioning the Assumptions. *Maternal Health and Child Journal*. 2010;15:1127-1134. doi:10.1007/s10995-010-0720-6

4. Chasnoff I, Landress H, Barrett M. The Prevalence of Illicit-Drug or Alcohol Use during Pregnancy and Discrepancies in Mandatory Reporting in Pinellas County, Florida. *New England Journal of Medicine*. 1990;322(17):1202-1206. doi:10.1056/NEJM199004263221706.

5. Substance Use During Pregnancy. Published online February 1, 2023. https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy

6. Haizler-Cohen L, Singhi V, Blau J, Galvin J, Fruhman G. Implementing universal urine drug screening upon admission to labor and delivery. *American Journal of Obstetrics and Gynecology*, 222(1):S88-S89. 7. Kunnis H, Bellin E, Chazotte C, Du E, Arnstein J. The Effect of Race on Provider Decisions to Test for Illicit Drug Use in the Peripartum Setting. *Journal of Womens Health*. 2010;16(2):245-255. doi:10.1089/jwh.2006.0070.

